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Abstract
Objectives: ACAT2 is the exclusive cholesterol-esterifying enzyme in hepatocytes and enterocytes. Hepatic ABCA1 transfers
unesterified cholesterol (UC) to apoAI, thus generating HDL. By changing the hepatic UC pool available for ABCA1, ACAT2
may affect HDL metabolism. The aim of this study was to reveal whether hepatic ACAT2 influences HDL metabolism.
Design: WT and LXRa/b double knockout (DOKO) mice were fed a western-type diet for 8 weeks. Animals were i.p. injected
with an antisense oligonucleotide targeted to hepatic ACAT2 (ASO6), or with an ASO control. Injections started 4 weeks
after, or concomitantly with, the beginning of the diet.
Results: ASO6 reduced liver cholesteryl esters, while not inducing UC accumulation. ASO6 increased hepatic ABCA1 protein
independently of the diet conditions. ASO6 affected HDL lipids (increased UC) only in DOKO, while it increased apoE-
containing HDL in both genotypes. In WT mice ASO6 led to the appearance of large HDL enriched in apoAI and apoE.
Conclusions: The use of ASO6 revealed a new pathway by which the liver may contribute to HDL metabolism in mice.
ACAT2 seems to be a hepatic player affecting the cholesterol fluxes fated to VLDL or to HDL, the latter via up-regulation of
ABCA1.
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Introduction
For many years, the inhibition of intracellular cholesterol
esterification has been considered as a potential strategy to prevent
atherosclerosis [1]. Acyl-coenzyme A:cholesterol acyltransferase
(ACAT) is an enzyme located in the endoplasmic reticulum that
catalyses the synthesis of cholesteryl esters (CE) by conjugating
cholesterol to long-chain fatty acids; mainly oleic and palmitic
acids. It is now clear that the two enzymes ACAT1 and ACAT2,
which are encoded by the Soat1 and Soat2 genes respectively,
localize in different cell types and have separate physiological
functions (for review see [2,3]). ACAT1 is ubiquitously expressed
and provides essential housekeeping functions to prevent the
toxicity induced by increasing amounts of unesterified cholesterol
(UC) in cells. Conversely, ACAT2 is exclusively expressed in
hepatocytes and enterocytes, and it synthesizes CE that can be
incorporated into apoB-containing lipoproteins (VLDL and
chylomicrons). In mice deletion of Soat1 or Soat2 genes revealed
a diverse role for the different ACAT enzymes in atherosclerosis.
In Soat1 knockout animals, ACAT1 deficiency led to a marked
alteration in cholesterol metabolism resulting in massive accumu-
lation of UC, which caused numerous skin and brain lesions, and
worsened atherosclerosis. Conversely, the deletion of the Soat2
gene has been consistently atheroprotective [4–6]. Previous studies
also suggest a clear atherogenic potential of ACAT2-derived CE
also in humans. In both women and men, the Atherosclerosis Risk
in Communities (ARIC) study revealed an association between the
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carotid intima-media thickness and the ACAT2-derived CE in
lipoproteins [7]. Also, the Uppsala Longitudinal Study of Adult
Men (ULSAM) showed an association between the ACAT2-
derived CE in lipoproteins and CVD mortality [8]. Finally,
ACAT2-derived CE in lipoproteins were able to predict coronary
artery disease in patients with symptoms of acute coronary
syndrome [9]. Athero-protection was also achieved in mice using
anti-sense oligonucleotide targeted to hepatic Soat2mRNA (ASO6)
and resulting in a decreased ACAT2 activity in the liver [10].
These studies did not address whether a decreased hepatic
ACAT2 activity modifies HDL metabolism. In addition, inconsis-
tent results on HDL cholesterol levels were obtained in mice in
which ACAT2 activity was reduced by genetic manipulation
[4,6,11–14]. We hypothesized that a low ACAT2 activity in the
liver would result in a greater UC mass that in turn could be
secreted into nascent HDL by ABCA1. Hence, we reduced
hepatic ACAT2 activity by injection of ASO6 in male C57BL/6
and in Liver X Receptor (LXR) a/b double knockout (DOKO)
mice. In DOKO mice the link between ACAT2 activity and HDL
metabolism should be more evident. This mouse model is
characterized by a reduced bile acid (BA) synthesis, which is
paralleled by a maintained ABCA1 expression in the liver.
Considering the possible fate of cholesterol in the hepatocytes (i.e.
the esterification by ACAT2 to be incorporated in VLDL or
stored, the conversion into BA, and the efflux into nascent HDL) a
reduction of the ACAT2 activity in DOKO mice, may indeed lead
to a greater UC mass available for secretion into nascent HDL.
Finally, we also investigated whether the metabolic response
following a decreased hepatic ACAT2 activity was influenced by
the time frame in which the animals were fed a western type of
diet.
Our results identify hepatic ACAT2 as an important player for
HDL metabolism since the activity of this enzyme may influence
the intracellular cholesterol fated to secretion either into VLDL or
into HDL particles; the latter via an increased expression of the
ABCA1 protein.
Material and Methods
Animals and experimental design
Ten-week-old male wild-type (WT), and LXRa and LXR b
double knockout (DOKO) mice, on a pure C57BL/6 genetic
background (as previously described [15]), were housed on a
regular 12-h light/12-h dark cycle with free access to water and
food. Until the onset of the studies, mice were fed a chow diet
(Special Diet Services; SDS, NOVA-SCB, Sweden – Rat and
Mouse n.1 Maintenance, 9.5 mm pellet; RM1 (P)). During the two
experiments animals were fed a western-type diet, containing 10%
saturated fat and 0.2% cholesterol (w/w) (Harlan Laboratories -
TD.07346, 4% PO, 2% SBO, 0.2% Cholesterol Diet - 1/2"
pellet). In the first experiment (4-weeks), the diet was started 4
weeks prior to and maintained during the following 4 weeks of
treatment with biweekly i.p. injection (25 MPK) of either an anti-
sense oligonucleotide specifically targeted to hepatic ACAT2 gene
(ASO 6) [10] in half of the animals, or with a control anti-sense
oligonucleotide (ASOctrl) in the other half. In the second
experiment (0-weeks) WT and DOKO mice were given the
western-type diet for 10 weeks and concomitantly treated with the
same doses of ASO6 and ASOctrl used in the 4-weeks experiment.
In all the experiments, animals were fasted 4 hours prior to
euthanasia, which was performed by inhalation of carbon dioxide.
Blood, tissues and organs were then collected, and stored at
280uC until the analyses. The Swedish Board of Agriculture,
Ethical committee on Animal Experiments, Stockholm South
approved all the animal studies (Permit number: S17-07, 2007-03-
30).
Antisense Oligonucleotides (ASOs)
The 5-10-5 methoxy ethyl chimeric 20-mer oligonucleotides
with fully modified phosphorothioate backbones were kindly
donated by ISIS Pharmaceuticals (Carlsbad, CA, USA). ASO6
contained a sequence-targeting mouse Soat2. The ASOctrl l was
not complementary to the ACAT2 sequence and did not hybridize




Isolation of liver microsomes and ACAT2 activity assay
Liver samples (50 to 150 mg) were homogenized in 3 mL ice-
cold buffer containing 0.1 mol/L K2HPO4, 0.25 mol/L sucrose,
and 1 mmol/L EDTA, pH 7.4. A protease inhibitor cocktail
(Sigma) was added to the buffer before homogenization. The
homogenate was then centrifuged for 15 min at 12 000 g (4uC) to
remove cell debris. The resulting supernatant was centrifuged for
60 min at 100 000 g. The microsomal pellet from this spin was re-
suspended in 0.1 mol/L K2HPO4 at pH 7.4 and immediately
frozen at –80uC. Total ACAT enzymatic activity was determined
in hepatic microsomes as previously described [16], except that
pre-incubation included a cholesterol-saturated solution of b-
hydroxypropyl cyclodextrin for 30 min before addition of 14[C]
oleoyl Co-A (PerkinElmer, Uppland Va¨sby, Sweden). In separate
tubes, pyripyropene A, a specific ACAT2 inhibitor [17], was
included in the preincubation at a concentration of 5 mmol/L to
differentiate ACAT1 (uninhibited) and ACAT2 (total–ACAT1)
activities. Pyripyropene A was a kind gift of Prof. Hiroshi Tomoda,
Dept. of Microbial Chemistry, Graduate School of Pharmaceutical
Sciences, Kitasato University, Japan.
Preparation of liver plasma membrane and western blot
analysis
Liver samples (, 200 mg) were homogenized in 3 mL ice-cold
buffer containing 20 mmol/LTris-HCl, 0.25 M sucrose, and
2 mmol/L MgCl2. A protease inhibitor cocktail (complete MINI
Roche Diagnostics GmbH, Mannheim, Germany) was added to
the buffer before homogenization. The homogenate was then
centrifuged for 10 min at 20006g (4uC) to remove fat. The
resulting intermediate phase was centrifuged for 45 min at
32000 rpm using a Beckman Ultracentrifuge XL-70. The pellet
was re-suspended in 100 ml of Lysis Buffer (80 mmol/L NaCl,
50 mmol/L Tris-HCl, 2 mmol/L CaCl2, 1% TritonX-100 and
protease inhibitor cocktail), and immediately frozen at –80uC.
After protein determination (DCTM protein assay, Bio-Rad
Laboratories, Hercules, USA) membranes were pooled group-
wise. Reduced pooled membranes (10, 20, 30 mg or 40, 60, 80 mg
protein) were separated on a NuPage 3–8% Tris-Acetate gel and
then transferred onto nitrocellulose membranes (Invitrogen,
Carlsbad, USA). After blocking in 5% non-fat dry milk in PBS-
T (PBS with 0.1% Tween-20), the nitrocellulose membranes were
incubated overnight at 4uC with the primary antibody (Ab) specific
for the protein of interest in 5% non-fat milk powder in PBS-T.
ABCA1 was detected with mouse monoclonal Ab (1:1000,
ab18180, Abcam LtD, Cambridge, UK) and as secondary
antibody a peroxidase-conjugated goat anti-mouse antibody was
used (1:20000; Pierce Biotechnology, Inc., Rockford). SR-BI was
detected with rabbit polyclonal Ab (1:3000, ab396, Abcam LtD,
Cambridge, UK) and a peroxidase-conjugated donkey anti-rabbit
ACAT2 and HDL Metabolism
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antibody (1:60000; GE Healthcare, UK). LDLr protein was
detected with rabbit monoclonal Ab (1:3000, ab52818, Abcam
LtD, Cambridge, UK) and a peroxidase-conjugated donkey anti-
rabbit antibody (1:60000; GE Healthcare, UK). The specific
bands were detected using SuperSignal chemiluminescence kit
(Pierce Biotechnology, Inc., Rockford) and Bio-Rad Universal
Hood II and quantified by Bio-Rad Quantity One software (Bio-
Rad Laboratories, Hercules, USA). Signals were plotted by mg-
loaded protein and the slope of the curves was calculated by
method of least square. The slope of the ASOctrl group was set
equal to 100%.
Serum and liver lipid analysis
Serum lipoproteins were fractionated by size from 12 mL of
individual serum samples using a Superose 6 PC 3.2/30 column
(GE Healthcare Bio-Sciences AB, Uppsala, Sweden) as previously
described [18]. The respective lipoprotein fraction lipid concen-
trations were calculated after integration of the individual
chromatograms. ApoAI and apoE content was determined in
the lipoprotein fractions by western blot analysis using an anti-
mouse apoA-I (Rockland, Gilbertsville, PA, USA) and an anti-
mouse apoE (Calbiochem, Merk, Darmstadt, Germany) as
primary antibody. Lipids were extracted from ,100 mg liver
sample using 6 mL chloroform-methanol (2:1 v/v). The organ was
removed from the tubes containing the lipid extract, which was
then dried down under N2 and re-dissolved in a measured volume
of 2:1 chloroform/methanol. Diluted H2SO4 was added to the
extract, which was then vortexed and centrifuged to split the
phases. The aqueous upper phase was aspirated and discarded,
and an aliquot of the bottom phase was removed and dried down.
1% Triton X-100 in chloroform was then added, and the solvent
was evaporated [19]. Lipids were quantified on Tecan GENios
plate reader equipped with Magellan Software (Tecan Group Ltd,
Switzerland) using the respective enzymatic kit: Cholesterol/HP,
Triglyceride/GB (Roche Diagnostics, Indianapolis, USA), and
Free Cholesterol C (Wako Chemicals USA Inc.). The amount of
esterified cholesterol was calculated by subtracting the unesterified
cholesterol from the total cholesterol, and this difference was
multiplied by 1.67 to convert it to CE mass. Liver lipid levels were
normalized for the hepatic protein content measured according to
Lowry method in the tissues digested with NaOH (1 mol/L). To
obtain a relative index of hepatic bile acid synthesis, the
concentration of 7a-hydroxy-4-cholesten-3-one (C4) was assayed
in the liver lipid extract by isotope dilution-mass spectrometry as
previously reported, and the ratio of C4 to total cholesterol was
calculated [20,21].
Cell culture and materials
Cell culture media, trypsin-EDTA, and gentamicin were
purchased from Gibco/Invitrogen (Paisley, Scotland). Fetal bovine
serum (FBS), serum albumin, the ACAT inhibitor Sandoz 58-035,
and 8-(4-Chlorophenylthio)adenosine 39,59-cyclic monophosphate
sodium salt (cpt-cAMP) were from Sigma-Aldrich (Stockholm,
Sweden). [1,2-3H(N)]-cholesterol was from PerkinElmer (Uppland
Va¨sby, Sweden). Tissue culture flasks, plates, and tubes were from
Thermo Fisher Scientific/Nunc (Roskilde Site, Denmark) or Falcon
(Lincoln, NY, USA). Human serum, prepared from blood of healthy
donors, was provided by the Dept. of Clinical Immunology and
Transfusion Medicine, Karolinska University Hospital, Huddinge,
Sweden (http://www.karolinska.se/Karolinska-Universitetslabora-
toriet/Kliniker/Immunologi-transfusionsmedicin/). The blood was
donated for general research purposes. The donors gave informed
consent that the blood could be used for preparation of serum for
research purposes, but were not explicitly asked about consent to
publish data. All samples were anonymized, i.e. not possible to trace
back to the blood donor. Ethical permission was not warranted for
requiring blood components per se, as this did not pose any extra
harm to the donors (regular blood donation was performed). Lipid
poor apoA-I isolated was isolated and purified from human serum as
previously described [22]. J774.A1 murine macrophages were
purchased from American type culture cell (LGC standards AB),
and maintained in RPMI with L-Glutamine plus 10% FBS and
gentamicin in 5% CO2. Fu5AH rat hepatoma cells [23–26] were a
kind gift of Prof. Franco Bernini (Dept. of Pharmacy, University of
Parma, Italy). Fu5AH were cultured in High glucose DMEM plus
10% FBS and gentamicin. Ultima GoldTM was from PerkinElmer
(Uppland Va¨sby, Sweden).
Quantification of serum cholesterol efflux capacity (CEC)
Mouse sera from the 4-weeks and 0-weeks experiment were
tested as cholesterol acceptors in different cell models to evaluate
the CEC. J774 murine macrophages incubated with cpt-cAMP
were used as a model of total cholesterol efflux, since all the efflux
pathways are active [27,28]. J774 cultured under basal conditions
were used to evaluate the aqueous diffusion [26,27]. The ABCA1-
mediated cholesterol efflux was the difference between the
cholesterol efflux measured by J774 incubated with cpt-cAMP
and the cholesterol efflux measured by J774 cultured in basal
condition [26,27]. SR-BI mediated cholesterol efflux was mea-
sured using Fu5AH rat hepatoma cells, a stable highly SR-BI-
expressing cell line [29]. In brief, cells were plated into 24-well
plates in medium containing 10% FBS. Monolayers were washed
with PBS and incubated for 24 h in medium containing 1% FBS,
[1,2-3H(N)]-cholesterol and ACAT inhibitor (2 mCi/mL). Cells
were then incubated for 18 h with medium plus 0.2% BSA and
ACAT inhibitor (2 mCi/mL), with 0.3 mmol/L cpt-cAMP when
appropriate. Cells were then harvested with NaOH (1 M) and
counted by liquid scintillation. These cells provided baseline (time
0) values for total [1,2-3H(N)]-cholesterol content. Cell monolayers
were then incubated with 1% (v/v) mouse serum in medium for
4 h. Cell media were centrifuged to remove floating cells, and
radioactivity in the supernatant was determined by liquid
scintillation counting. Cholesterol efflux was calculated as: (cpm
in medium at 4 h/cpm at time 0) x 100. For each experiment
aimed to measure the serum CEC by ABCA1, we monitored
ABCA1 up-regulation in J774 cells as increased efflux to human
apoA-I (20 mg/mL) from cells treated with cpt-cAMP compared to
untreated cells. Pooled human serum from 20 healthy donors was
tested in every experiment as an acceptor (2% v/v) in order to
monitor and correct for the inter-assay variability in cholesterol
efflux.
2D gel electrophoresis
Serum HDL subclasses were separated by 2D electrophoresis, in
which agarose gel electrophoresis was followed by non-denaturing
polyacrylamide gradient gel electrophoresis and subsequent
immunoblotting [23]. In the first dimension, serum (5 mL) was
run on a 0.5% agarose gel; agarose gel strips containing the
separated lipoproteins were then transferred to a 3-20%
polyacrylamide gradient gel. Separation in the second dimension
was performed at 30 mA for 4 h. Fractionated HDLs were then
electroblotted onto a nitrocellulose membrane and detected with
an anti-mouse apoA-I (Rockland, Gilbertsville, PA, USA) or an
anti-mouse apoE (Calbiochem, Merck, Darmstadt, Germany)
antibody and visualized by enhanced chemiluminescence (GE
Healthcare Biosciences, Uppsala, Sweden). Densitometric analysis
was performed with a GS-690 Imaging Densitometer and the
Multi-Analyst software (Bio-Rad Laboratories, Hercules, CA,
ACAT2 and HDL Metabolism
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USA). Serum content of preb-HDL was expressed as percentage
of total apoA-I.
RNA extraction, cDNA synthesis, and qPCR analysis of
mRNA expression levels
RNA from liver tissue was isolated using RNeasy Mini Kit
(QIAGEN GmbH, Hilden, Germany) according to the manufac-
turer’s protocol. The concentration and quality of the purified
total RNA were determined spectrophotometrically at OD260 nm
and by the OD260/280 ratio, respectively. Synthesis of single-
stranded cDNA was carried out on 0.5 mg RNA using iScript
cDNA synthesis kit (Bio-Rad Laboratories, Inc., Hercules, CA)
following a standard protocol. PCR primers were designed using
Primer Express Software version 2.0, a program especially
provided for primer design using ABI qPCR machines. qPCR
assay on the basis of SYBR Green I technology was performed
with ABI 7500 fast qPCR system (Applied Biosystems, Foster City,
CA). For each pair of primers, a dissociation curve analysis was
conducted to validate the specificity of the PCR amplification.
Primers were used at a concentration of 100 mmol/L in qPCR
analyses and the sequences are listed in Table S1. We calculated
relative changes employing the comparative method using Tfiib as
the reference gene and controls as calibrators as indicated in the
figures.
Statistical analysis
Statistics was calculated using Statistica software (Stat Soft Inc.,
USA). As indicated in the text or in each figure, differences
between the treatment groups were determined by the Mann
Whitney test. Multi-way analysis of variance (ANOVA) test
followed by post-hoc comparisons of group means according to
the least significant difference (LSD) method was used when
comparing the effect of treatment in the different mouse
genotypes. Outlier rejection was performed prior to the analysis.
Mean, standard error of the mean (SEM), and p-values were used
for descriptive purposes. A p-value ,0.05 was considered
statistically significant.
Results
In order to control for the efficacy of ASO6 treatment, we
examined Soat2 expression in the two organs where ACAT2 is
exclusively expressed [3], the intestine and liver. In agreement
with previous studies [13], ASO6 administration led to a specific
down-regulation of ACAT2 in the liver (Figure 1 A) without
modifying the expression in proximal or distal intestine (Figure 1
B, C). When the feeding with the western type of diet was started 4
weeks after the ASO injection (4-weeks), ASO6 reduced hepatic
Soat2 mRNA by about 80% in both WT and DOKO mice. The
reduction of Soat2 was coupled with more than 80% reduction in
the liver microsomal activity of ACAT2 in both genotypes (ASO6
vs ASOctrl: 0.0860.01 vs 1.2160.14 ng/mg/min in WT,
p,0.005; and 0.1560.03 vs 0.8660.06 ng/mg/min, p,0.01; in
DOKO respectively). Also when the diet challenge was started
concomitantly with the treatment (0-weeks), a similar reduction of
liver microsomal activity of ACAT2 was observed in both WT
(ASO6 vs ASOctrl: 0.0360.004 vs 0.5560.10 ng/mg/min;
p,0.005) and DOKO (ASO6 vs ASOctrl: 0.1460.02 vs
0.6860.06; p,0.005) mice. As seen in the 4-weeks experiment,
the reduction in ACAT2 activity followed a significant reduction
in hepatic Soat2 mRNA expression in both genotypes (Figure 1A).
Liver lipid content in ASO6 treated mice
We evaluated the lipid content in the liver samples from all the
experiments performed. As ASO6 treatment reduced hepatic
ACAT2 activity more then 80% in both the 4-weeks and 0-weeks
experiment, hepatic CE mass was diminished. As shown in
Figure 1D, ASO6 treatment in the 4-weeks experiment reduced
hepatic CE levels by 91% in WT mice, whereas only a 30%
reduction was observed in DOKO mice receiving ASO6. A
similar effect was observed in the 0-weeks experiment where
ASO6 lowered hepatic CE levels up to 91% in WT and up to 50%
in DOKO mice. Hepatic ACAT2 knock down by ASO6 did not
result in accumulation of UC in the liver as previously observed in
a different mouse genotype [13]. In the 4-weeks experiment
hepatic UC was not affected by ASO treatment in either WT or
DOKO mice, whereas in the 0-weeks experiment ASO6 led to a
21% reduction of hepatic UC only in WT mice (Figure 1E).
ACAT2 knockdown has been reported to alter triglyceride (TG)
metabolism in mice, thus lowering hepatic TG levels [30]. We
quantified the hepatic TG content in both the 4-weeks and 0-
weeks experiments (Figure 1F). In WT mice ASO6 lowered
hepatic TG, although significantly only in the 0-weeks experiment.
Liver TG mass was not affected by ASO6 in DOKO mice, which
showed decreased hepatic TG levels compared to their wild type
counterparts independently of the treatment (p,0.001 and
p,0.01 in the 4-weeks and 0-weeks experiments respectively;
Factorial ANOVA). In order to assess whether hepatic ACAT2
knock down induces BA synthesis, and to confirm that LXR
DOKO mice have a reduced synthesis, we also quantified hepatic
C4. As shown in Figure 1G, in both experimental conditions
ASO6 led to an increase of liver C4 content in both WT and
DOKO mice. As expected C4 levels in DOKO mice were
significantly lower that in WT mice independently of the
treatment (4-weeks and 0-weeks: p,0.001, Factorial ANOVA).
ACAT2 activity and ABCA1 expression in the liver
Since we did not observe any accumulation of UC following
hepatic ACAT2 down-regulation, we hypothesized that UC could
be channelled into nascent HDL through the ABCA1 transporter,
whose expression was analysed at both mRNA, and protein levels
in liver membranes. In the 4-weeks experiment, ASO6 treatment
of WT induced a 133% increase in hepatic ABCA1 protein,
whereas no effects were observed at the mRNA level (Figure 2A).
In DOKO mice (Figure 2B) ASO6 led to a 171% increase of the
ABCA1 protein compared to ASOctrl. Abca1 mRNA was slightly
reduced by ACAT2 down-regulation in this mouse genotype. Also
in the 0-weeks experiment, hepatic ACAT2 depletion by ASO6
led to about a doubling of the ABCA1 protein expression in liver
membranes of both WT and DOKO mice (Figure 2 C and D.
However, under these experimental conditions the Abca1 mRNA
levels increased in WT mice (Figure 2C).
Serum lipid lipoprotein profile
The analysis of the serum lipid profile revealed that in WT mice
ASO6 did not affect the total levels of TC or UC (Table 1). Instead
it led to a redistribution of cholesterol within the different
lipoprotein fractions (Figure 3 A, B, E, F). As expected the
reduction of ACAT2 expression in the liver reduced TC in the
VLDL fractions (4-weeks: 0.2560.02 vs 0.5660.09 mmol/L,
p,0.005; 0-weeks: 0.1560.03 vs 0.6660.09 mmol/L, p,0.005).
Interestingly in the TC serum lipoprotein profile, ASO6 treatment
led to the appearance of a new peak between LDL and HDL
particles in both experiments (Figure 3A and E). This effect was
even more pronounced when the distribution of UC in serum
lipoproteins was analysed (Figure 3B, F), and it was also present
ACAT2 and HDL Metabolism
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when phospholipids (PL) were analysed (Figure 4). In order to
further characterize this new peak, pooled serum from WT mice
from the 0-weeks experiment was separated by size exclusion
chromatography (SEC), and lipoprotein fractions were collected.
Figure 1. Effect of hepatic ACAT2 down regulation on Soat2 expression, and on the liver lipid content. Soat2 mRNA was quantified by
real-time RT-PCR in samples from liver (A), proximal (B) and distal intestine (C). Data were standardized for Tfiib mRNA expression, and normalized to
WT Ctrl in each experiment. Cholesteryl ester (CE; D), unesterified cholesterol (UC; E), and triglyceride (TG; F) mass was measured in liver lipid extracts
by enzymatic assays as described in the methods section. Cholesteryl esters were calculated subtracting the mass of unesterified cholesterol to total
cholesterol, and adjusted for the mass of the moiety of fatty acid in CE. Liver lipid levels were normalized for the hepatic protein content. 7a-hydroxy-
4-cholesten-3-one (C4; G) mass was measured in the liver lipid extracts by LC-MS/MS, and normalized for the hepatic total cholesterol (TC) mass. Error
bars represent the median. Mann Whitney test, * p,0.05, ** p, 0.01, *** p,0.001.
doi:10.1371/journal.pone.0093552.g001
ACAT2 and HDL Metabolism
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Analysis of apoA-I and apoE content by Western blot revealed an
increased content of both these apolipoproteins in the fractions (nr
30-39) corresponding to the lipoprotein peak formed by ASO6
treatment (Figure 4). In DOKO mice ASO6 treatment did not
change the plasma levels of TC, but led to an increase in serum
UC (Table 1). This effect was more pronounced in the 0-weeks
experiment. In the 4-weeks experiment DOKO mice receiving
ASO6 showed higher levels of TC in the HDL lipoprotein
fractions compared to ASOctrl treated animals (Figure 3E, F). In
both experiments ASO6 treatment strongly increased the HDL-
UC in DOKO mice (Table 1 and Figure 3D, H). In both WT and
DOKO mice from the 4-weeks experiment down-regulation of
ACAT2 increased serum TG levels in the apoB-containing
lipoprotein fraction (1.1660.06 vs 0.7460.09 mmol/L in WT,
p,0.01; 0.2960.05 vs 0.0960.01 mmol/L in DOKO, p,0.01).
In the 0-weeks experiment, this effect was only observed in
DOKO mice (0.7260.08 vs 0.5260.05 mmol/L in WT;
0.3560.03 vs 0.0860.01 mmol/L in DOKO, p,0.005).
Effect of ACAT2 disruption on serum cholesterol efflux
capacity (CEC)
Since changes in serum lipid profiles were observed in both WT
and DOKO mice treated with ASO6, we investigated whether the
effect on HDL fractions would affect the capacity of serum to
accept cholesterol from macrophages. CEC is strictly related to the
composition of the lipoproteins present in the serum, and more
importantly to the capacity of the different HDL subclasses to act
as a lipid acceptor [26]. Thus, serum samples from all the
Figure 2. Hepatic ACAT2 down regulation increases the ABCA1
protein independently of the mRNA expression. Liver membrane
proteins were pooled group-wise, loaded, and separated on Tris-
Acetate Gels. After transfer onto nitrocellulose membrane, samples
were incubated with anti-mouse ABCA1 antibody. ABCA1 band (<
250 kD) was detected by chemiluminescence, and signals were plotted
by mg-loaded protein. The slope of the curves was calculated by
method of least square, and the slope of the ASOctrl group was set
equal to 100%. Hepatic Abca1 mRNA was quantified by real-time RT-
PCR. Data were standardized for Tfiib mRNA expression, and normalized
to WT Ctrl in each experiment. In the mRNA data error bars represent
the median. Mann Whitney test, ** p, 0.01.
doi:10.1371/journal.pone.0093552.g002 Figure 3. Effect of hepatic ACAT2 down regulation on serum
lipoprotein profile. Serum lipoproteins were separated by size
exclusion chromatography, and the total (left panels) and unesterified
cholesterol (right panels) content was determined by a system for on-
line detection. Black solid lines are the average chromatogram for the
ASOctrl treated group, and grey solid lines are the average
chromatogram for the ASO6 treated group (n = 6–8). Lipoprotein
profiles of WT mice are shown in panels A, B, E, and F. Lipoprotein
profiles of LXR DOKO mice are represented in panels C, D, H and G.
doi:10.1371/journal.pone.0093552.g003
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experiments were tested using cAMP-treated J774 macrophages as
cholesterol donors [27]. As shown in Figure 5, serum from both
WT and DOKO mice treated with ASO6 was a more efficient
cholesterol acceptor than serum from ASOctrl treated mice, but
this was seen only in the 4-weeks experiment. No differences in
serum CEC were observed comparing serum from ASO6 treated
WT and DOKO mice with their respective control from the 0-
weeks experiment.
Effect of ASO6 on HDL subclasses
The presence of specific HDL subclasses determines HDL
functionality and serum CEC. Therefore, we investigated whether
ASO6 could affect the distribution of the HDL particle, providing
us with a possible explanation for the effects we observed on the
lipid lipoprotein profile and serum CEC. HDL were separated by
2D gel electrophoresis, and immunoblotted against apoA-I or
apoE. As shown in Figure 6 (left panels), in WT mice from the 4-
Figure 4. Hepatic ACAT2 down regulation led to formation of apoE-rich HDL. Serum samples from WT mice treated with ASO6 or ASOctrl
were pooled (n = 3–6) and ultracentrifugated. Lipoproteins with a density , 1.21 g/L were then separated by SEC, collecting the lipoprotein fractions
every 3 min. As described in the method section, apolipoprotein (apo) AI and E content (A) were determined in the different fractions by western blot
analysis. Phospholipids (PL) were quantified enzymatically.
doi:10.1371/journal.pone.0093552.g004
Table 1. Lipid quantification in serum and HDL lipoproteins.
4-weeks 0-weeks
mmol/L WT ASOctrl WT ASO6 DOKO ASOctrl DOKO ASO6 WT ASOctrl WT ASO6 DOKO ASOctrl DOKO ASO6
TC 5.3060.33 5.5460.21 6.1060.30 5.3060.27 4.8760.36 4.2660.41 7.6760.24 6.3360.59
HDL-TC 4.2360.26 4.6260.17 2.1560.05 2.8760.28 3.7860.34 3.6860.33 2.6560.12 2.4960.39
UC 1.4560.11 1.6460.17 1.4560.07 2.0160.29 1.2960.11 1.3960.14 2.5560.14 4.6660.88*
HDL-UC 1.1360.12 1.1760.14 0.4160.01 1.0460.10{ 0.9160.08 1.0460.10 0.7260.06 1.9460.27{
PL 5.8760.61 7.0760.29 4.4560.23 6.4160.60* 5.6560.26 5.3360.27 5.1160.21 5.4460.57
HDL-PL 5.0360.61 6.4560.32 2.4660.17 4.6060.17{ 4.8260.22 4.6160.22 2.5060.37 3.5460.39
TG 1.0960.13 1.2960.06 0.2260.02 0.4360.05* 0.5860.04 0.7860.07 0.1360.01 0.4860.11`
HDL-TG 0.3560.09 0.1360.03 0.1260.03 0.1460.01 0.0660.01 0.0660.01 0.0660.01 0.0560.02
Serum lipoproteins were separated by size exclusion chromatography, and the concentration of total (TC) and unesterified (UC) cholesterol, phospholipids (PL), and
triglycerides (TG) was determined by a system for on-line detection. Data are expressed as average 6 SEM (n = 6–8). Mann Whitney test, *p,0.05, { p,0.01, ` p,0.005.
doi:10.1371/journal.pone.0093552.t001
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weeks experiment ASO6 treatment did not affect the pre-b-HDL,
but led to the appearance of larger a-particles. Conversely in
DOKO mice, hepatic ACAT2 down-regulation induced the
appearance of smaller a-HDL, and significantly increased the
pre-b-HDL content. For both mouse genotypes from the 0-weeks
experiment, no differences were observed in HDL subclasses
between ASO6 and ASOctrl treatment (Figure 6 right panels).
In both experiments ASO6 increased the amount of apoE-
containing HDL, without modifying the particle size (Figure 6
bottom panels). In the 4-weeks experiment we observed an
average of 26% increase in apoE-containing HDL when WT
ASO6 treated mice were compared to randomly selected ASOctrl
treated animals. For DOKO mice the average increase was 128%.
In the 0-weeks experiment the average increase in apoE-
containing HDL of ASO6 treated WT mice was of 122%, while
in DOKO mice was about 100%. In both genotypes from the 4-
weeks and 0-weeks experiment, apoE-containing HDL from
ASO6 treated animals showed a progressive shift of migration
towards preb position.
Figure 5. Impact of hepatic ACAT2 down regulation on serum
CEC. J774 murine macrophages were radiolabeled with [3H]-cholesterol
for 24 h, equilibrated in a BSA-containing medium 6 cpt-cAMP
0.3 mmol/L for 18 h. Efflux was measured after 4 h of cell incubation
with medium containing 1% serum from WT (black bars) and LXR DOKO
(grey bars) mice treated with ASOctrl (empty bars) or ASO6 (filled bars).
Efflux is expressed as cpm in medium/cpm T0 6 100. Error bars
represent the median. Mann Whitney test, ** p,0.01.
doi:10.1371/journal.pone.0093552.g005
Figure 6. Hepatic ACAT2 knock-down modifies HDL subclasses. HDL subclasses were separated by non-denaturing two-dimensional gel
electrophoresis and transferred onto a nitrocellulose membrane, on which lipoproteins were detected with an anti-mouse apoA-I or apoE antibody; a
representative animal in each group is shown. Preb-HDL content was calculated as percentage of total apoA-I signal from 2D-electrophoresis
developed against apoA-I. Error bars represent the median. Mann Whitney test, * p,0.05.
doi:10.1371/journal.pone.0093552.g006
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Changes in HDL subclasses and cholesterol efflux
mechanisms
In the 4-weeks experiment, hepatic ACAT2 down-regulation
led to changes in apoA-I-containing particle distribution and
resulted in increased capacity of serum to promote cholesterol
efflux from macrophages. Since cholesterol efflux occurs by several
mechanisms characterized by a preferential acceptor [31], serum
samples from the 4-weeks experiment were tested for their
cholesterol acceptor capacity using different cell lines selectively
expressing specific lipid transporters. Reflecting the presence of
larger mature HDL secondary to hepatic ACAT2 knockdown,
serum from ASO6 treated WT mice showed increased capacity to
promote cholesterol efflux by aqueous diffusion and by SR-BI
transporter when compared to serum from ASOctrl treated WT
(Figure S1 A and B). Serum from ASO6 treated DOKO mice was
more efficient than serum from DOKO mice treated by ASOctrl,
in promoting cholesterol efflux through the ABCA1 transporters
(Figure S1 C). Indeed, in DOKO mice ASO6 treatment resulted
in increased serum levels of pre-b-HDL (Figure 4), which have
been demonstrated to be a preferential acceptor for the ABCA1-
mediated efflux [32]. Efflux via aqueous diffusion (AD) was also
increased to serum from DOKO mice when hepatic ACAT2 was
reduced.
Effect of hepatic ACAT2 down-regulation on genes
involved in lipid metabolism
The reduced hepatic ACAT2 activity by ASO treatment ought
to affect the pool of UC that can signal to and activate the LXR
system. Surprisingly, no consistent LXR activation was observed
in any of the experiments, as assessed by the hepatic gene profile of
LXR target genes (Table 2). Cyp7a1 and Abcg5; were not affected
by the ASO6 treatment, whereas Abcg8 and Scd1 were respectively
increased only in WT and DOKO from the 0-weeks experiment.
A decreased hepatic ACAT2 activity appeared to result in a down-
regulation of the genes under control of the SREBP2 system, but
only in WT mice from the 4-weeks experiment (Table 2). Indeed
ASO6 treatment resulted in reduced mRNA expression of Ldlr,
Pcsk9, Hmgcr and Hmgcs (see Table 2 and Figure S2). Some of these
effects were also seen in DOKO mice (Table 2). However, hepatic
ACAT2 down-regulation did not reduce the expression of
SREBP2 target genes when the dietary challenge was started
together with ASO6 treatment (0-weeks; Table 2). As shown in
Figure S2, LDLr protein expression was analysed in liver
membrane pools. In the 4-weeks experiment hepatic ACAT2
down-regulation did not affect LDLr protein in WT (Figure S2 A),
whereas it reduced the receptor by 98% in DOKO mice (Figure
S2 C). A similar reduction was also observed in DOKO animals
from the 0-weeks experiment (Figure S2 G).
In spite of the minor effects seen for TG content in the liver of
WT animals (see above), in the 4-weeks experiment ASO6
treatment reduced the mRNA of genes involved in fatty acid
synthesis, which was likely mediated by a SREBP1-c down-
regulation (i.e. Fasn and Acc1; Table 2). However, in the 0-weeks
experiment, we did not observe this effect. In these experimental
conditions, ASO6 increased Scd1 and Acc1 mRNA levels in the
liver of DOKO mice (Table 2). Triacylglycerol hydrolase 1 and 2
mRNA expression was significantly reduced in LXR DOKO mice
compared to WT independently of the treatment (4-weeks: Tgh1,
p,0.01 and Tgh2, p,0.001; 0-weeks: Tgh1, p,0.001 and Tgh2,
p,0.001; Factorial ANOVA). ASO6 did affect the expression of
these genes in WT mice (Table 2). Only in the 4-weeks experiment
and in DOKO mice did ACAT2 down-regulation lead to slightly
increased Tgh1 mRNA levels (Table 2). We also evaluated the
hepatic expression of the HDL receptor SR-BI, both at mRNA
and protein levels. As shown in Figure S2 (right panels), hepatic
ACAT2 down-regulation led to a reduction of SR-BI protein
expression in the liver membranes, without affecting the mRNA.
In the 4-weeks experiment ASO6 reduced SR-BI by 28% and 6%
in WT and DOKO respectively (Figure S2 B and D). In the 0-
weeks experiment hepatic ACAT2 down-regulation led to a
reduction in SR-BI protein expression by 8% in WT and 36% in
DOKO mice (Figure S2 F and H).
Discussion
Our main aim with this study was to uncover a possible link
between hepatic ACAT2 activity and HDL metabolism in mice.
We hypothesized that the excess of UC in the hepatocytes due to a
lower activity of ACAT2 may be also shunted into nascent HDL
by ABCA1. In order to better unravel this mechanism we decided
to include LXR a/b double knockout mice in our experiments. In
these animals UC should be more available to secretion in to
nascent HDL because of lower bile acid synthesis paralleled by a
maintained ABCA1 expression in the liver.
We have previously reported that the hepatic ABCA1 protein
was up-regulated when the expression of hepatic ACAT2 was
reduced, independently of the levels of Abca1 mRNA expression
[33]; an effect also seen in apoB100only-LDLr2/2 mice [13]. In
mice where ACAT2 was selectively knocked out in the liver,
hepatic Abca1 mRNA was increased [14]. However, the protein
expression of ABCA1 was not reported in these studies. Here we
clearly demonstrate that down-regulation of hepatic ACAT2
activity results in a strong stimulation of ABCA1 protein
expression in liver membranes, and that this process is definitively
independent from LXRs. The up-regulation of the ABCA1
protein expression results from an as yet unidentified post-
transcriptional process, since it is clearly independent of Abca1
mRNA expression. Intracellular UC may play a role since it has
been shown that UC loading induces ABCA1 expression in several
cell models [34]. Wang et al showed that hepatocytes from mice
depleted of NPC1 accumulate FC and have an up-regulation of
ABCA1 protein. Cathespin D, a lysomal proteinase, has been
proposed as a possible player in this upregulation [35]. Further-
more Rab8 over-expression was found to increase ABCA1 protein
in human primary macrophages, without affecting the mRNA
levels [36]. Finally, palmitoylation of ABCA1 by the palmitoyl
transferase DHHC8 is essential for its localization at the plasma
membrane and contributes to its efflux function [37]. In the
present work, we quantified the mRNA expression of these genes
(Table 2), and found that ACAT2 downregulation did not affect
their expression. However, we cannot completely exclude their
participation in the ABCA1 up-regulation, since only the mRNA
expression was evaluated.
The liver is the major organ for HDL synthesis (by lipidation of
apoA-I through ABCA1) as shown by the study of liver-specific
ABCA1 knockout mice [38]. Whether ACAT2 disruption in mice
would have an impact on HDL metabolism was unclear, since
previous studies have shown contrasting results on the lipid
content in HDL [4,6,11–14]. In apoE knockout [4] and LDLr
knockout [6] mice an increase in HDL cholesterol was observed
when ACAT2 was knocked out. However, no changes in HDL
lipid composition were observed in different ACAT22/2 mouse
genotypes [12,13], or in mice where ACAT2 was selectively
knocked out in the liver or intestine [14]. In the present work we
showed that after ASO6 treatment decreased hepatic ACAT2,
HDL lipid composition changed only in DOKO mice (increased
levels of HDL-UC). Hepatic Lcat mRNA was not affected by
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ASO6 treatment suggesting that the HDL-UC increase is not
mediated by a reduction in the levels of this enzyme.
HDL lipoproteins are not just simple lipid carriers, but are a
complex and heterogeneous class of particles, differing in physical
and chemical properties, protein and lipid composition, metabo-
lism and functions [39]. Treatment of WT mice with ASO6
revealed the appearance of a new peak in the serum lipoprotein
profile, which elutes between the typical peak for LDL and HDL
particles. We demonstrated that these newly generated lipopro-
teins are large HDL particles enriched in apoA-I and apoE. Thus,
reduction of hepatic ACAT2 activity does not change plasma lipid
levels, but rather leads to a redistribution of lipids within the
different lipoprotein particles. The newly generated particle
appeared independently of the dietary conditions, as was the
increase in hepatic ABCA1 expression. This effect could not be
observed from the lipid profile of DOKO mice. The big peak
generated by the increase in HDL-UC could have possibly masked
the peak of the new generated particles for this mouse genotype.
Interestingly, large apoE-rich HDL particles seem to be associated
with increased hepatic ABCA1 protein expression. This phenom-
enon has been observed in mice treated with the LXR agonist
T090137 [40], in mice overexpressing hepatic ABCA1 [41], and
in transgenic mice expressing human NPC1L1in the liver [42].
Lipid poor apoE can directly interact with ABCA1 and be
lapidated [43]. This process generates particles with a preb-
migration, and a diameter ranging between 9 and 15 nm [43]. By
2D-gel electrophoresis analysis, we found that ASO6 treatment
increased the amount of apoE-containing HDL in both WT and
LXR DOKO mice, and that the apoE-containing HDL formed
show a progressive shift of migration towards preb position and an
estimated size between 12 and 15 nm. This effect was independent
of the dietary challenges.
We also investigated if the changes in HDL metabolism
secondary to hepatic ACAT2 knock down resulted in improved
HDL functionality. Thus, we measured the capacity of serum to
promote cholesterol efflux. This parameter and the different
mechanisms involved in cholesterol efflux have been shown to be
strongly dependent on the different HDL sub-classes present in the
circulation [26,44]. Indeed, we observed that only when the apoA-
I containing particle distribution was modified by ASO6
treatment, serum cholesterol efflux capacity was increased.
Importantly, we showed that changes in the efflux pathways
involved reflected the changes in preb- and a-HDL subclasses.
These effects were observed only when the western type diet was
started prior to the ASO6 treatment, but not when diet and
treatment were started concomitantly. In our study we found that
serum CEC is positively correlated with both serum and HDL PL
content (Figure S3). When the diet was started concomitantly with
the treatment ASO6 did not alter the serum PL content,
conversely to what observed when the diet was started 4 weeks
before the ASO6 treatment. This effect may partly explain the lack
of increased serum CEC we observed when the diet was started
concomitantly with the ASO6 treatment. It has been shown
previously that cellular cholesterol efflux is strongly dependent on
the phospholipid content of the extracellular acceptor [32,45,46].
In the hepatocytes cholesterol can be esterified by ACAT2 and
packed into VLDL, or fluxed into nascent HDL or converted into
bile acids. In the present study we also demonstrated that hepatic
ACAT2 knock down led to an increased bile acid synthesis, as
shown by the higher levels of 7a-hydroxy-4-cholesten-3-one in the
liver of the ASO6 treated mice.
Another important finding in this study is the unexpected lack of
LXR activation in response to the down-regulation of hepatic
ACAT2 activity. No evident changes in mRNA abundance of the
Table 2. Hepatic expression of genes involved in lipid metabolism.
4-weeks 0-weeks
Gene (a.u.) WT ASOctrl WT ASO6 DOKO ASOctrl DOKO ASO6 WT ASOctrl WT ASO6 DOKO ASOctrl DOKO ASO6
Srebp2 0.9260.04 0.6360.13 1.2560.17 0.9360.05 0.9960.14 1.1760.41 0.3060.04 0.3060.01
Hmgcr 1.1560.12 0.52460.10* 0.8460.06 0.5760.05* 2.7761.03 1.8860.33 0.1760.02 0.2860.10
Hmgcs 1.2560.23 0.4360.16* 0.9060.09 0.5560.11* 0.4060.13 0.3260.08 0.1060.01 0.1860.06*
Pcsk9 1.5160.39 0.1860.07{ 0.2360.08 0.0860.02 1.4760.35 1.6760.48 0.1960.05 0.3060.14
Lcat 0.7560.09 0.8160.15 0.9660.10 0.6560.11 0.7860.07 0.8160.04 0.2360.03 0.2560.0
Lipc 1.3260.21 1.5060.29 0.8160.09 0.6760.24 0.7160.21 0.6860.11 0.2360.0 0.1560.07
Cyp7a1 2.3061.17 4.2361.10 1.2960.25 0.8060.16 1.7460.50 1.9860.37 0.2460.08 0.3760.16
Abcg5 1.3760.22 1.1860.30 0.2460.03 0.1660.02 2.7861.03 1.8860.33 0.1760.02 0.2860.10
Abcg8 1.5460.26 1.7460.60 0.3460.03 0.2460.04 1.5460.23 2.6360.41* 0.6560.10 0.4560.12
Scd1 2.8660.77 1.6960.52 0.0260.01 0.0260.00 1.4360.27 1.1460.17 0.00460.00 0.0160.01*
Fasn 1.5060.33 0.1560.05` 0.0460.01 0.0360.01 1.4560.56 1.4760.31 0.0560.00 0.0560.02
Acc1 1.5060.33 0.4260.10` 0.3860.02 0.2660.03 1.4360.27 1.1360.17 0.00460.00 0.0160.01*
Srebp1c 0.6060.15 0.3460.17 0.00160.0 0.0060.00 0.6160.14 1.2160.23 0.0060.00 0.0060.00
Tgh1 1.8460.30 1.6460.17 0.5060.04 0.7260.0{ 1.2960.18 1.4760.36 0.2660.04 0.3760.15
Tgh2 1.5560.16 1.4460.04 0.1760.03 0.0760.01 1.2660.20 0.8460.21 0.0560.01 0.1360.07
Ctsd 3.9461.88 0.6860.17 5.7861.45 2.8760.47 0.8360.14 0.9160.20 1.5160.24 0.7760.24
Zdhhc8 1.1360.23 1.2860.24 3.0260.96 2.4060.53 0.5960.09 0.7460.12 0.4960.06 0.4760.10
Rab8a 0.8460.07 1.0660.24 2.2660.41 1.5960.39 0.6660.10 0.9460.20 0.2860.02 0.4360.14
mRNA was quantified by real-time RT-PCR. Data were standardized for Tfiib mRNA expression, and normalized to the expression of each gene in WT Ctrl in each single
experiment. mRNA data are expressed as average 6 SEM (n = 6–8). Mann Whitney test, *p,0.05, { p,0.01, ` p,0.005.
doi:10.1371/journal.pone.0093552.t002
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classical LXR target genes were observed upon ASO6 treatment.
Conversely, decreased hepatic cholesterol esterification in mice led
to a down-regulation of the SREBP2 transcriptional pathway since
the abundance of Ldlr, Pcsk9, Hmgc reductase and synthase mRNA
were decreased. However, this was only evident when the liver was
preloaded with dietary cholesterol before down-regulation of
ACAT2 activity, since no effects on SREBP2 target genes were
observed when ASO6 treatment was started concomitantly with
dietary cholesterol challenge. In this latter experimental condition
treatment of WT mice with ASO6, the levels of hepatic UC were
reduced, and this difference may explain some of the discrepancies
observed between the 4-weeks and 0-weeks experiment.
In LXR DOKO compared to WT mice, ACAT2 down-
regulation was less effective in reducing hepatic CE in both
experiments. For the first time, we have shown here that Tgh1 and
Tgh2 expression is extremely low in LXRa/b double knockout
mice. Since carboxylesterases can also catalyse the hydrolysis of
CE, the reduced expression of Tgh1 and Tgh2 observed in LXR
DOKO may explain the elevated CE content in the livers of LXR
DOKO mice, as well as the failure to mobilize it by hydrolysis
upon reduction of cholesterol esterification by ASO6 treatment.
A limitation of our study can be represented by the fact that we
only investigated liver lipid storage/synthesis, hepatic conversion
of cholesterol into bile acids and HDL formation process. Two
other important pathways of the hepatic lipid metabolism (i.e.
VLDL production and biliary cholesterol secretion) have not been
evaluated even if they are known to play a role in HDL
metabolism. However the effect of ACAT2 deletion on these
pathways has been previously studied. It has been shown that the
total apoB accumulation rate in liver perfusate from ACAT2 KO
mice was not different from that of their respective littermates
[47], and ASO6 treatment led to a reduction of biliary cholesterol
secretion in apoB100only-LDLr2/2 mice [13].
It is known that ASOs can present non-target effect. In the
present work we did not test the effect of ASO6 treatment in
ACAT2 knock out (KO) mice to rule out that possibility.
Nevertheless, we ran a third experiment (data not shown) feeding
ACAT2 KO animals and their respective littermates for 6 weeks
with the same western type of diet used in the ASOs experiments.
ACAT2 KO showed a similar phenotype to that we observed by
ASO6 treatment. Compared to their littermates, ACAT2 KO
mice showed double the expression of ABCA1 protein in the
hepatic liver membranes together with the appearance of the new
HDL lipoprotein particle peaks in the lipid profile.
In conclusion, the use of anti-sense oligonucleotide targeted to
hepatic ACAT2 revealed a new pathway by which the liver may
contribute to HDL metabolism in mice. ACAT2 seems to be an
important hepatocyte player that influences intracellular choles-
terol fluxes either into VLDL lipoproteins or into HDL particles,
the latter via the up-regulated ABCA1 transporter. The relevance
of these findings for the human condition does not seem to be
futile. A negative correlation between the hepatic ACAT2 activity
and the plasma levels of HDL cholesterol and apoA-I was
described in normolipidemic non-obese Chinese patients [48], and
a functional variant of the SOAT2 gene was identified as an
independent genetic determinant of plasma HDL cholesterol levels
in the LCAS and TexGen cohorts [49]. Thus SOAT2 has been
listed among those genes that influence HDL plasma level in
humans [50]. Also, it is worth to remember that treatment with
ASO6 generates a condition in mice similar to that in humans,
where a low hepatic activity of ACAT2 [51] is present together
with elevated intestinal ACAT2 activity [52]. Mice and non-
human primates have high hepatic ACAT2 activity [3]. However,
the lack of plasma CETP activity [53] or the high rate of
hydrolysis of triglyceride rich lipoproteins positively influences the
genesis of HDL respectively in these two species. In humans, low
hepatic ACAT2 activity may be needed to keep up the lipidation
of apoAI. Considering the role of HDL for innate immunity
[54,55], a low hepatic ACAT2 activity may have been a strong
evolutionary advantage.
Supporting Information
Figure S1 Efflux mechanisms involved in serum choles-
terol efflux capacity (CEC). Cells were radiolabeled with
[3H]-cholesterol for 24 h, equilibrated in a BSA-containing
medium for 18 h and exposed for 4 h to 1% serum from WT
(left panels) and LXR DOKO (right panels) mice treated with
ASOctrl or ASO6. SR-BI-mediated efflux (A) was assessed in
Fu5AH rat hepatoma cells; aqueous diffusion-mediated efflux (B)
was assessed in J774 macrophages; ABCA1-mediated efflux (C)
was assessed in J774 macrophages: ABCA1 contribution was
calculated as the difference between the efflux determined in J774
cells treated with cpt-cAMP 0.3 mM or grown under basal
condition. Mean and SEM are shown. Mann Whitney test,
*p,0.05; **p,0.01.
(TIF)
Figure S2 Effect of hepatic ACAT2 down regulation on
LDLr and SR-B expression in the liver. Liver membrane
proteins were pooled group-wise, loaded, and separated on Tris-
Acetate Gels. After transfer onto nitrocellulose membrane,
samples were incubated with anti-mouse LDLr or SR-BI antibody.
LDLr band (< 140 kD), and SR-BI bands (< 75 kD free and
<50 kD glycosylated form) were detected by chemiluminescence,
and signals were plotted by mg-loaded protein. The slope of the
curves was calculated by method of least square, and the slope of
the ASOctrl group was set equal to 100%. Hepatic Ldlr and Srb1
mRNA were quantified by real-time RT-PCR. Data were
standardized for Tfiib mRNA expression, and normalized to WT
Ctrl in each experiment. mRNA data are expressed as average 6
SEM (n= 6–8). Mann Whitney test, * p, 0.05.
(TIF)
Figure S3 Correlation between serum cholesterol efflux
capacity, serum and HDL phospholipids.
(TIF)
Table S1 Sequences of the mouse primers.
(DOCX)
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